Diabetes patients’ cost-sharing is increasing as PBMs and health plans are paying less for insulin products. While this situation defies logic, it reflects an imperfect market in which it’s not necessarily in the PBMs’ and health plans’ interests to engage in a fully competitive marketplace.
Rising Out-Of-Pocket Costs For Insulin Indicates Market Failure
